Trial Profile
To predict response to 18F-FDG PET/CT to chemotherapy in combination with Bevacizumab in patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Erlotinib; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Sep 2017 New trial record
- 01 Aug 2017 Results published in the Journal of Nuclear Medicine